249 related articles for article (PubMed ID: 26867495)
1. Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: A comparison of the reactivity of isoniazid with its known human metabolites.
Khan SR; Morgan AG; Michail K; Srivastava N; Whittal RM; Aljuhani N; Siraki AG
Biochem Pharmacol; 2016 Apr; 106():46-55. PubMed ID: 26867495
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil peroxidase oxidizes isoniazid to form the active metabolite against M. tuberculosis, isoniazid-NAD
Babu D; Morgan AG; Reiz B; Whittal RM; Almas S; Lacy P; Siraki AG
Chem Biol Interact; 2019 May; 305():48-53. PubMed ID: 30922765
[TBL] [Abstract][Full Text] [Related]
3. Isoniazid as a substrate and inhibitor of myeloperoxidase: identification of amine adducts and the influence of superoxide dismutase on their formation.
Forbes LV; Furtmüller PG; Khalilova I; Turner R; Obinger C; Kettle AJ
Biochem Pharmacol; 2012 Oct; 84(7):949-60. PubMed ID: 22846601
[TBL] [Abstract][Full Text] [Related]
4. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities.
Cade CE; Dlouhy AC; Medzihradszky KF; Salas-Castillo SP; Ghiladi RA
Protein Sci; 2010 Mar; 19(3):458-74. PubMed ID: 20054829
[TBL] [Abstract][Full Text] [Related]
6. Isonicotinic acid hydrazide conversion to Isonicotinyl-NAD by catalase-peroxidases.
Wiseman B; Carpena X; Feliz M; Donald LJ; Pons M; Fita I; Loewen PC
J Biol Chem; 2010 Aug; 285(34):26662-73. PubMed ID: 20554537
[TBL] [Abstract][Full Text] [Related]
7. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant.
Zhao X; Yu H; Yu S; Wang F; Sacchettini JC; Magliozzo RS
Biochemistry; 2006 Apr; 45(13):4131-40. PubMed ID: 16566587
[TBL] [Abstract][Full Text] [Related]
8. Free radicals produced during the oxidation of hydrazines by hypochlorous acid.
Goodwin DC; Aust SD; Grover TA
Chem Res Toxicol; 1996 Dec; 9(8):1333-9. PubMed ID: 8951237
[TBL] [Abstract][Full Text] [Related]
9. A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts.
Nguyen M; Claparols C; Bernadou J; Meunier B
Chembiochem; 2001 Dec; 2(12):877-83. PubMed ID: 11948876
[TBL] [Abstract][Full Text] [Related]
10. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
11. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
12. Role of superoxide in catalase-peroxidase-mediated isoniazid action against mycobacteria.
Wang JY; Burger RM; Drlica K
Antimicrob Agents Chemother; 1998 Mar; 42(3):709-11. PubMed ID: 9517959
[TBL] [Abstract][Full Text] [Related]
13. Superoxide reactivity of KatG: insights into isoniazid resistance pathways in TB.
Ghiladi RA; Cabelli DE; Ortiz de Montellano PR
J Am Chem Soc; 2004 Apr; 126(15):4772-3. PubMed ID: 15080669
[TBL] [Abstract][Full Text] [Related]
14. Phenylbutazone Oxidation via Cu,Zn-SOD Peroxidase Activity: An EPR Study.
Aljuhani N; Whittal RM; Khan SR; Siraki AG
Chem Res Toxicol; 2015 Jul; 28(7):1476-83. PubMed ID: 26090772
[TBL] [Abstract][Full Text] [Related]
15. Catalase-peroxidases (KatG) exhibit NADH oxidase activity.
Singh R; Wiseman B; Deemagarn T; Donald LJ; Duckworth HW; Carpena X; Fita I; Loewen PC
J Biol Chem; 2004 Oct; 279(41):43098-106. PubMed ID: 15280362
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism for the activation of the anti-tuberculosis drug isoniazid by Mn(III): First detection and unequivocal identification of the critical N-centered isoniazidyl radical and its exact location.
Qin L; Huang CH; Xu D; Xie LN; Shao J; Mao L; Kalyanaraman B; Zhu BZ
Free Radic Biol Med; 2019 Nov; 143():232-239. PubMed ID: 31319159
[TBL] [Abstract][Full Text] [Related]
18. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
[TBL] [Abstract][Full Text] [Related]
19. Evidence for isoniazid-dependent free radical generation catalyzed by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T).
Wengenack NL; Rusnak F
Biochemistry; 2001 Jul; 40(30):8990-6. PubMed ID: 11467961
[TBL] [Abstract][Full Text] [Related]
20. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.
Nguyen M; Quémard A; Broussy S; Bernadou J; Meunier B
Antimicrob Agents Chemother; 2002 Jul; 46(7):2137-44. PubMed ID: 12069966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
